Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity-Reference-Cited by-同舟云学术

Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity

Published:2021-08 Issue: Volume:119 Page:105368
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Karabajakian Andy,Bouaoud Jebrane,Michon Lucas,Kamal Maud,Crozes Carole,Zrounba Philippe,Auclair-Perossier Jessie,Gadot Nicolas,Attignon Valéry,Le Tourneau Christophe,Benzerdjeb Nazim,Fayette Jérôme,Saintigny Pierre

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference44 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin.,2018

2. Chemotherapy for recurrent/metastatic head and neck cancers;Karabajakian;Anticancer Drugs,2017

3. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck;Ferris;N Engl J Med.,2016

4. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression;Ferris;Oral Oncol,2018

5. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study;Cohen;Lancet,2019

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: A bi-institutional retrospective concordance analysis (CONCORDL-1 study);Oral Oncology;2024-10

2. Standardized Digital Image Analysis of PD-L1 Expression in Head and Neck Squamous Cell Carcinoma Reveals Intra- and Inter-Sample Heterogeneity with Therapeutic Implications;Cancers;2024-05-31

3. Radiomics and PD-L1 expression predict immunotherapy benefits in patients with head and neck squamous cell carcinoma;FUTURE ONCOL;2024

4. Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes;Oral Oncology;2024-02

5. Programmed Cell Death Ligand 1 Immunoexpression in Head and Neck Squamous Cell Carcinoma: A Narrative Review of Considerations for the Histopathologist;JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH;2024